Affiliation:
1. Instituto de Matemática e Estatística, Departamento de Ciência da Computação, Universidade de São Paulo, Rua do Matão 1010, São Paulo 05508-090, SP, Brazil
2. Children’s Cancer Institute, Porto Alegre 90620-110, RS, Brazil
3. Departamento de Física, Universidade Federal de Santa Maria, Santa Maria 97105-900, RS, Brazil
Abstract
It is well established that microRNA-21 (miR-21) targets phosphatase and tensin homolog (PTEN), facilitating epithelial-to-mesenchymal transition (EMT) and drug resistance in cancer. Recent evidence indicates that PTEN activates its pseudogene-derived long non-coding RNA, PTENP1, which in turn inhibits miR-21. However, the dynamics of PTEN, miR-21, and PTENP1 in the DNA damage response (DDR) remain unclear. Thus, we propose a dynamic Boolean network model by integrating the published literature from various cancers. Our model shows good agreement with the experimental findings from breast cancer, hepatocellular carcinoma (HCC), and oral squamous cell carcinoma (OSCC), elucidating how DDR activation transitions from the intra-S phase to the G2 checkpoint, leading to a cascade of cellular responses such as cell cycle arrest, senescence, autophagy, apoptosis, drug resistance, and EMT. Model validation underscores the roles of PTENP1, miR-21, and PTEN in modulating EMT and drug resistance. Furthermore, our analysis reveals nine novel feedback loops, eight positive and one negative, mediated by PTEN and implicated in DDR cell fate determination, including pathways related to drug resistance and EMT. Our work presents a comprehensive framework for investigating cellular responses following DDR, underscoring the therapeutic potential of targeting PTEN, miR-21, and PTENP1 in cancer treatment.
Funder
São Paulo Research Foundation
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Reference85 articles.
1. Entezari, M., Taheriazam, A., Orouei, S., Fallah, S., Sanaei, A., Hejazi, E.S., Kakavand, A., Rezaei, S., Heidari, H., and Behroozaghdam, M. (2022). LncRNA-miRNA Axis in Tumor Progression and Therapy Response: An Emphasis on Molecular Interactions and Therapeutic Interventions. Biomed. Pharmacother., 154.
2. MicroRNA-21’s Role in PTEN Suppression and PI3K/AKT Activation: Implications for Cancer Biology;Chawra;Pathol.-Res. Pract.,2024
3. The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics;Mol. Ther. Nucleic Acids,2020
4. MicroRNA-21 as a Diagnostic Marker for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis;Qu;Pak. J. Med. Sci.,2019
5. miR-21 Promotes Cell Migration and Invasion of Hepatocellular Carcinoma by Targeting KLF5;Wang;Oncol. Lett.,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献